NYSE:NVRO - Nevro Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$45.46 -0.34 (-0.74 %)
(As of 01/23/2019 04:00 PM ET)
Previous Close$45.80
Today's Range$44.37 - $45.90
52-Week Range$34.75 - $94.34
Volume480,683 shs
Average Volume895,119 shs
Market Capitalization$1.37 billion
P/E Ratio-36.37
Dividend YieldN/A
Beta-0.12
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$326.67 million
Book Value$8.41 per share

Profitability

Net Income$-36,650,000.00

Miscellaneous

Employees676
Market Cap$1.37 billion
OptionableOptionable

Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) announced its earnings results on Monday, November, 5th. The medical equipment provider reported ($0.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.07. The medical equipment provider had revenue of $95.60 million for the quarter, compared to analyst estimates of $94.29 million. Nevro had a negative return on equity of 17.89% and a negative net margin of 11.64%. The firm's quarterly revenue was up 16.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.21) earnings per share. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Nevro.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $386.9-387.4 million, compared to the consensus revenue estimate of $385.46 million.Nevro also updated its Q4 2018 guidance to EPS.

What price target have analysts set for NVRO?

11 Wall Street analysts have issued 1 year target prices for Nevro's stock. Their predictions range from $35.00 to $105.00. On average, they anticipate Nevro's stock price to reach $59.5455 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price. View Analyst Price Targets for Nevro.

What is the consensus analysts' recommendation for Nevro?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nevro.

What are Wall Street analysts saying about Nevro stock?

Here are some recent quotes from research analysts about Nevro stock:
  • 1. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019)
  • 2. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (1/10/2019)

Has Nevro been receiving favorable news coverage?

Media stories about NVRO stock have trended negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near future.

Who are some of Nevro's key competitors?

Who are Nevro's key executives?

Nevro's management team includes the folowing people:
  • Mr. Rami Elghandour, Pres, CEO & Director (Age 40)
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Cerebellum GP LLC (0.02%) and Bank of Montreal Can (0.01%). Company insiders that own Nevro stock include Andrew H Galligan, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.

Which institutional investors are buying Nevro stock?

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Cerebellum GP LLC. View Insider Buying and Selling for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $45.46.

How big of a company is Nevro?

Nevro has a market capitalization of $1.37 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.

What is Nevro's official website?

The official website for Nevro is http://www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


MarketBeat Community Rating for Nevro (NYSE NVRO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel